FDA Approved Products
4,491 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
ATACAND
candesartan cilexetil
LOE Approaching
ANI Pharmaceuticals
ORAL · TABLET
hypertension in adultschildren 1 to <17 years of age+7
1998
NDA30/100
ATACAND HCT
candesartan cilexetil and hydrochlorothiazide
LOE Approaching
ANI Pharmaceuticals
ORAL · TABLET
hypertensionto lower blood pressure+1
2000
NDA30/100
ATARAX
hydroxyzine hydrochloride
LOE Approaching
Pfizer
ORAL · TABLET
anxiety
1956
NDA30/100
ATARAX
hydroxyzine hydrochloride
LOE Approaching
Pfizer
ORAL · SYRUP
anxiety
1956
NDA30/100
ATIVAN
lorazepam
LOE Approaching
Bausch + Lomb
ORAL · TABLET
anxiety disordersfor the short-term relief of the symptoms of anxiety+2
1977
NDA30/100
ATIVAN
lorazepam
LOE Approaching
Hikma
INJECTION · INJECTABLE
status epilepticusproducing sedation (sleepiness+4
1980
NDA30/100
ATNAA
atropine and pralidoxime chloride
LOE Approaching
Medica Corp
INTRAMUSCULAR · INJECTABLE
poisoning by susceptible organophosphorus nerve agents having anticholinesterase activity in adults
2002
NDA30/100
ATRALIN
tretinoin
LOE Approaching
TOPICAL · GEL
2007
NDA30/100
ATRIDOX
doxycycline hyclate
LOE Approaching
PERIODONTAL · SYSTEM, EXTENDED RELEASE
the following infections: Rocky Mountain spotted fevertyphus fever+11
1998
NDA30/100
ATROMID-S
clofibrate
LOE Approaching
Thayer Medical
ORAL · CAPSULE
1967
NDA30/100
ATROPEN
atropine
LOE Approaching
Medcaptain Medical Technology
INTRAMUSCULAR · SOLUTION
poisoning by susceptible organophosphorus nerve agents having cholinesterase activitycarbamate insecticides in adult
1973
NDA30/100
ATROPINE SULFATE
atropine sulfate
LOE Approaching
Pfizer
INTRAVENOUS · SOLUTION
2001
NDA30/100
ATROPINE SULFATE
atropine sulfate
LOE Approaching
Medica Corp
INHALATION · AEROSOL, METERED
older for: Atropine is an anticholinergic agent indicated in adultsolder for: Cycloplegia () Mydriasis () Penalization of the healthy eye in the treatment of amblyopia () 1
1990
NDA30/100
ATROVENT
ipratropium bromide
LOE Approaching
Boehringer Ingelheim
INHALATION · SOLUTION
COPDchronic obstructive pulmonary disease
1993
NDA30/100
ATROVENT
ipratropium bromide
LOE Approaching
Boehringer Ingelheim
NASAL · SPRAY, METERED
COPDchronic obstructive pulmonary disease
1995
NDA30/100
ATROVENT
ipratropium bromide
LOE Approaching
Boehringer Ingelheim
NASAL · SPRAY, METERED
COPDchronic obstructive pulmonary disease
1995
NDA30/100
ATROVENT
ipratropium bromide
LOE Approaching
Boehringer Ingelheim
INHALATION · AEROSOL, METERED
COPDchronic obstructive pulmonary disease
1986
NDA30/100
AUGMENTIN '125'
amoxicillin; clavulanate potassium
LOE Approaching
Pfizer
ORAL · TABLET, CHEWABLE
infections due to susceptible strains of designated microorganismsthe treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species+4
1985
NDA30/100
AUGMENTIN '125'
amoxicillin and clavulanate potassium
LOE Approaching
Pfizer
ORAL · FOR SUSPENSION
the following infections in adultsskin structure infections Urinary tract infections Limitations of Use+12
1984
NDA30/100
AUGMENTIN '200'
amoxicillin; clavulanate potassium
LOE Approaching
Pfizer
ORAL · FOR SUSPENSION
infections due to susceptible strains of designated microorganismsthe treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species+4
1996
NDA30/100
AUGMENTIN '200'
amoxicillin; clavulanate potassium
LOE Approaching
Pfizer
ORAL · TABLET, CHEWABLE
infections due to susceptible strains of designated microorganismsthe treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species+4
1996
NDA30/100
AUGMENTIN '250'
amoxicillin; clavulanate potassium
LOE Approaching
Pfizer
ORAL · TABLET, CHEWABLE
1985
NDA30/100
AUGMENTIN '250'
amoxicillin and clavulanate potassium
LOE Approaching
Pfizer
ORAL · FOR SUSPENSION
the following infections in adultsskin structure infections Urinary tract infections Limitations of Use+12
1984
NDA30/100
AUGMENTIN '250'
amoxicillin; clavulanate potassium
LOE Approaching
Pfizer
ORAL · TABLET
infections due to susceptible strains of designated microorganismsthe treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species+4
1984
NDA30/100